drugset / Trial / NCT00003700
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Phase 2
Completed
163 enrolled
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have untreated acute lymphoblastic leukemia.
Timeline
- Start
- 1999-01
- Primary completion
- 2004-02
- Completion
- 2010-01
Publications
- Results Stock W, Yu D, Johnson J, et al.: Intensified Daunorubicin during induction and post-remission therapy of adult acute lymphoblastic leukemia (ALL): results of CALGB 19802. [Abstract] Blood 102 (11 Pt 1): A-1375, 2003.
- Results Stock W, Dodge RK, Vardiman JW, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): phase II trial of dose intensification of Daunorubicin and Cytarabine followed by high-dose Methotrexate and intrathecal Methotrexate in place of cranial irradiation (CALGB 19802). [Abstract] Blood 98 (11 Pt 1): A-2472, 2001.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 1200 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Subject | Daunorubicin | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Daunorubicin | Small molecule | 80 mg/m2 | Intravenous |
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | 60 mg/m2 | Oral |
| Subject | Methotrexate | Small molecule | 15 mg | Intrathecal |
| Subject | Methotrexate | Small molecule | 25 mg/m2 | Intrathecal |
| Subject | Methotrexate | Small molecule | 1000 mg/m2 | Intrathecal |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | Oral |
| Subject | Vincristine | Small molecule | 2 mg | Intravenous |
| Subject | asparaginase | Protein / enzyme biologic | 6000 unknown | Subcutaneous |
| Background | Allopurinol | Small molecule | 300 mg | Oral |
| Background | G-CSF | Unknown | 5 ug/kg | Subcutaneous |
| Background | Leucovorin | Small molecule | 5 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 25 mg/m2 | Intravenous |